Colorado
Denver; The Urology Center of Colorado
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Florida
Gainesville; Gainesville Hematology/ Oncology Associates
A Randomized Phase II Study Of The Efficacy And Safety of Sunitinib Malate Schedule Four Weeks On And Two Weeks Off Versus Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RENAL EFFECT TRIAL)
Georgia
Atlanta; Emory University
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Illinois
Elgin; Sherman Health Systems
Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Elgin; Sherman Health Systems
The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR
Indiana
Beech Grove; St. Francis Hospital and Health Centers
AS1411-C-202: A Phase II, Open Label, Single Arm Study of AS1411 in Patients with Metastatic Renal Cell Carcinoma
Indianapolis; The Indiana Cancer Center
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Iowa
Iowa City; University of Iowa
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Kansas
Kansas City; University of Kansas Hospital
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Minnesota
Minneapolis; University of Minnesota Cancer Center
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Nevada
Las vegas; Nevada Cancer Institute
The purpose of this study are to determine the safety profile of MDX-1411; determine the maximum tolerated dose (MTD); and determine the dose-limiting toxicity (DLT) of MDX-1411 when administered every 14 days to subjects with advanced or recurrent clear cell renal cell carcinoma (ccRCC)
New Hampshire
Lebanon; Dartmouth-Hitchcock Medical Center
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
New York
Manhasset; Biomedical Research Alliance of New York
A clinical trial evaluate the safety and efficacy of a study drug versus placebo in patients with a clear cell renal cell carcinoma and a high risk of recurrence
Manhasset; Biomedical Research Alliance of New York, LLC
Study for high risk recurrence of renal cell carcinoma after surgical treatment
Manhasset; Biomedical Research Alliance of New York
A clinical trial evaluate the safety and efficacy of a study drug versus placebo in patients with a clear renal cell carcinoma and a high risk of recurrence
New York; Memorial Sloan Kettering Cancer Center
The purpose of this study are to determine the safety profile of MDX-1411; determine the maximum tolerated dose (MTD); and determine the dose-limiting toxicity (DLT) of MDX-1411 when administered every 14 days to subjects with advanced or recurrent clear cell renal cell carcinoma (ccRCC)
New York; Biomedical Research Alliance of New York
A clinical trial evaluate the safety and efficacy of a study drug versus placebo in patients with a clear cell renal cell carcinoma and a high risk of recurrence
New York; Mount Sinai Medical Center
A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage? Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma.
North Carolina
Charlotte; Blumenthal Cancer Center
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Ohio
Cleveland; Cleveland Clinic Taussig Cancer Center
The purpose of this study are to determine the safety profile of MDX-1411; determine the maximum tolerated dose (MTD); and determine the dose-limiting toxicity (DLT) of MDX-1411 when administered every 14 days to subjects with advanced or recurrent clear cell renal cell carcinoma (ccRCC)
Oregon
Portland; Portland Providence Medical Center
The purpose of this study are to determine the safety profile of MDX-1411; determine the maximum tolerated dose (MTD); and determine the dose-limiting toxicity (DLT) of MDX-1411 when administered every 14 days to subjects with advanced or recurrent clear cell renal cell carcinoma (ccRCC)
Texas
Dallas; CORTPA
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Virginia
Charlottesville; University of Virginia
Children with Chronic Renal Insufficiency and taking Growth Hormone are needed for a research study
International
Montreal, QC, Canada; Jewish General Hospital
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Toronto, ON, Canada; Princess Margaret Hospital
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
